{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:21:30Z","timestamp":1790727690196,"version":"4.1.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Maine et Loire Committee"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.drudis.2018.05.040","type":"journal-article","created":{"date-parts":[[2018,6,2]],"date-time":"2018-06-02T02:18:39Z","timestamp":1527905919000},"page":"1936-1949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Advances in treatment formulations for acute myeloid leukemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Thomas","family":"Briot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-1745","authenticated-orcid":false,"given":"Emilie","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Th\u00e9pot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-0673","authenticated-orcid":false,"given":"Frederic","family":"Lagarce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2018.05.040_bib0005","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/annonc\/mdl443","article-title":"Epidemiology of hematological malignancies","volume":"18","author":"Rodriguez-Abreu","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjh.12425","article-title":"Survival and cure of acute myeloid leukaemia in England, 1971\u20132006: a population-based study","volume":"162","author":"Shah","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0015","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/510677","article-title":"Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts","volume":"44","author":"Segal","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drudis.2018.05.040_bib0020","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11912-017-0574-9","article-title":"Prophylactic measures during induction for acute myeloid leukemia","volume":"19","author":"McCarthy","year":"2017","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.drudis.2018.05.040_bib0025","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1002\/ajh.24847","article-title":"Intensive consolidation with G-CSF support: tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients >\/=60 years","volume":"92","author":"Sperr","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0030","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(14)70282-7","article-title":"Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study","volume":"15","author":"Sant","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0035","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3324\/haematol.12304","article-title":"Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century","volume":"93","author":"Pulte","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.drudis.2018.05.040_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2008-05-157065","article-title":"Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients","volume":"113","author":"Sekeres","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0045","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1182\/blood-2012-09-454553","article-title":"Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia","volume":"121","author":"Bertoli","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0050","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0055","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother. Rep."},{"key":"10.1016\/j.drudis.2018.05.040_bib0060","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.beha.2017.10.001","article-title":"How can one optimize induction therapy in AML?","volume":"30","author":"Luger","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0065","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa0901409","article-title":"High-dose daunorubicin in older patients with acute myeloid leukemia","volume":"361","author":"Lowenberg","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.05.040_bib0070","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1200\/JCO.2011.40.3642","article-title":"Superior long-term outcome with idarubicin compared with high-dose daunorubicin in patients with acute myeloid leukemia age 50 years and older","volume":"31","author":"Gardin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0075","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"Dohner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0080","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.05.040_bib0085","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.25","article-title":"Acute promyelocytic leukemia: where did we start, where are we now, and the future","volume":"5","author":"Coombs","year":"2015","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.drudis.2018.05.040_bib0090","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0095","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.05.040_bib0100","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0105","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 Trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0110","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s00277-017-3161-0","article-title":"The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia","volume":"96","author":"Nassereddine","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0115","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.drudis.2018.05.040_bib0120","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2018.05.040_bib0125","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0130","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V128.22.1070.1070","article-title":"Determination of IDH1 mutational burden and clearance via next-generation sequencing in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class inhibitor of mutant IDH1","volume":"128","author":"DiNardo","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0135","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.drudis.2018.05.040_bib0140","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and efficacy of venetoclax (Ven) in combination with decitabine or azacitidine in treatment-naive, elderly patients (\u226565 years) with acute myeloid leukemia (AML): a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0145","series-title":"Oral presentation given during EHA22, Abstract S473, June 24th 2017","article-title":"Updated safety and clinical results of phase 1\/2 study of Venetoclax plus low-dose cytarabine in treatment-naive acute myeloid leukemia patients aged \u226565 years and unfit for standard induction therapy","author":"Wei","year":"2017"},{"key":"10.1016\/j.drudis.2018.05.040_bib0150","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2017-08-784066","article-title":"Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML","volume":"130","author":"Wei","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2015-07-604538","article-title":"Emerging therapeutic drugs for AML","volume":"127","author":"Stein","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0160","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0165","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2018.05.040_bib0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood.V128.22.342.342","article-title":"Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)","volume":"128","author":"Pemmaraju","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0175","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","article-title":"Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0185","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0190","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1634\/theoncologist.2015-0298","article-title":"The European Medicines Agency Review of decitabine (Dacogen) for the treatment of adult patients with acute myeloid leukemia: summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use","volume":"21","author":"Nieto","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2018.05.040_bib0195","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0200","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/leu.2014.244","article-title":"Novel drugs for older patients with acute myeloid leukemia","volume":"29","author":"Montalban-Bravo","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2018.05.040_bib0205","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-017-0463-6","article-title":"Emerging therapies for acute myeloid leukemia","volume":"10","author":"Saygin","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0210","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/phar.2039","article-title":"Midostaurin: a new oral agent targeting FMS-like tyrosine kinase 3-mutant acute myeloid leukemia","volume":"37","author":"Stansfield","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drudis.2018.05.040_bib0215","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0220","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1200\/JCO.2012.43.4738","article-title":"Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia","volume":"30","author":"Mrozek","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0225","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1080\/17425255.2016.1215423","article-title":"ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview","volume":"12","author":"Arrigoni","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0230","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/sj.leu.2404859","article-title":"ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia","volume":"21","author":"Raaijmakers","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2018.05.040_bib0235","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.drudis.2018.05.040_bib0240","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acs.molpharmaceut.6b01150","article-title":"Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: physicochemical characteristics, in vitro mechanistic studies, and ex vivo patient derived therapeutic efficacy","volume":"14","author":"Guo","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0245","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1038\/leu.2015.139","article-title":"Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia","volume":"29","author":"Dorrance","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2018.05.040_bib0250","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J Control. Release"},{"key":"10.1016\/j.drudis.2018.05.040_bib0255","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: a review of recent success in drug delivery","volume":"6","author":"Tran","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.drudis.2018.05.040_bib0260","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.ddtec.2011.12.001","article-title":"Overcoming poor oral bioavailability using nanoparticle formulations \u2013 opportunities and limitations","volume":"9","author":"Desai","year":"2012","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0265","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1517\/17425255.2011.570330","article-title":"Pharmacokinetic and toxicity considerations for the use of anthracyclines in ovarian cancer treatment","volume":"7","author":"Morotti","year":"2011","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0270","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1021\/mp2001389","article-title":"Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells","volume":"8","author":"Riganti","year":"2011","journal-title":"Mol Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0275","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ijpharm.2010.02.014","article-title":"Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin","volume":"391","author":"Dicko","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0280","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1182\/blood-2013-12-540971","article-title":"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine\/daunorubicin, vs cytarabine\/daunorubicin in older adults with untreated AML","volume":"123","author":"Lancet","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0285","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","article-title":"Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells","volume":"39","author":"Kim","year":"2011","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0290","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/cncr.28974","article-title":"Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML","volume":"121","author":"Cortes","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.drudis.2018.05.040_bib0295","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/17474086.2017.1369400","article-title":"CPX-351 in acute myeloid leukemia: can a new formulation maximize the efficacy of old compounds?","volume":"10","author":"Brunetti","year":"2017","journal-title":"Expert Rev. Hematol."},{"issue":"Suppl","key":"10.1016\/j.drudis.2018.05.040_bib0300","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2016.34.15_suppl.7000","article-title":"Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML","volume":"34","author":"Lancet","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0305","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-06-0118","article-title":"Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice","volume":"5","author":"Mayer","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2018.05.040_bib0310","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2217\/nnm.13.123","article-title":"Liposomal codelivery of a synergistic combination of bioactive lipids in the treatment of acute myeloid leukemia","volume":"9","author":"Tan","year":"2014","journal-title":"Nanomedicine"},{"key":"10.1016\/j.drudis.2018.05.040_bib0315","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2011.11.002","article-title":"In vivo efficacy of a novel liposomal formulation of safingol in the treatment of acute myeloid leukemia","volume":"160","author":"Tan","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.drudis.2018.05.040_bib0320","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejpb.2014.04.002","article-title":"Efficacy of multi-functional liposomes containing daunorubicin and emetine for treatment of acute myeloid leukaemia","volume":"88","author":"Myhren","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0325","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fchem.2014.00087","article-title":"Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic","volume":"2","author":"Moreno","year":"2014","journal-title":"Front. Chem."},{"key":"10.1016\/j.drudis.2018.05.040_bib0330","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12943-017-0683-y","article-title":"Nano-based delivery of RNAi in cancer therapy","volume":"16","author":"Xin","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.drudis.2018.05.040_bib0335","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1172\/JCI84424","article-title":"Targeting noncoding RNAs in disease","volume":"127","author":"Adams","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2018.05.040_bib0340","first-page":"1243","article-title":"Liposome-incorporated Grb2 antisense oligodeoxynucleotide increases the survival of mice bearing bcr-abl-positive leukemia xenografts","volume":"31","author":"Tari","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0345","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/leu.2013.181","article-title":"A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia","volume":"27","author":"Metzeler","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.drudis.2018.05.040_bib0350","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","article-title":"Therapeutic targeting of acute myeloid leukemia stem cells","volume":"129","author":"Pollyea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0355","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/mp5008212","article-title":"CD33-targeted lipid nanoparticles (aCD33LNs) for therapeutic delivery of GTI-2040 to acute myelogenous leukemia","volume":"12","author":"Li","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0360","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.3109\/10428194.2013.838764","article-title":"Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed\/refractory acute myeloid leukemia","volume":"55","author":"Klisovic","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.drudis.2018.05.040_bib0365","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2018.05.040_bib0370","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad2355","article-title":"Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo","volume":"8","author":"Ashton","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drudis.2018.05.040_bib0375","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1158\/1535-7163.MCT-16-0580","article-title":"Optimizing therapeutic effect of Aurora B inhibition in acute myeloid Leukemia with AZD2811 nanoparticles","volume":"16","author":"Floc\u2019h","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.drudis.2018.05.040_bib0380","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2174\/157340612802084333","article-title":"Poly (d,l-lactic-co-glycolide) nanoparticles for the improved therapeutic efficacy of all-trans-retinoic acid: a study of acute myeloid leukemia (AML) cell differentiation in vitro","volume":"8","author":"Simon","year":"2012","journal-title":"Med. Chem."},{"key":"10.1016\/j.drudis.2018.05.040_bib0385","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.biopha.2016.11.121","article-title":"Novel transferrin modified and doxorubicin loaded Pluronic 85\/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation","volume":"86","author":"Zhu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2018.05.040_bib0390","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.leukres.2014.08.008","article-title":"Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells","volume":"38","author":"Gul-Uludag","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.drudis.2018.05.040_bib0395","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1182\/blood.V91.9.3401","article-title":"A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia","volume":"91","author":"Legras","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2018.05.040_bib0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044197","article-title":"Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines","volume":"7","author":"Landry","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2018.05.040_bib0405","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ejca.2010.02.024","article-title":"CD44, a therapeutic target for metastasising tumours","volume":"46","author":"Orian-Rousseau","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.drudis.2018.05.040_bib0410","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1208\/s12249-014-0113-z","article-title":"Polymeric micelles: nanocarriers for cancer-targeted drug delivery","volume":"15","author":"Zhang","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.drudis.2018.05.040_bib0415","doi-asserted-by":"crossref","first-page":"900","DOI":"10.2174\/138920021131400112","article-title":"Pharmacokinetics of polymeric micelles for cancer treatment","volume":"14","author":"Wang","year":"2013","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.drudis.2018.05.040_bib0420","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijpharm.2017.05.016","article-title":"Paclitaxel: What has been done and the challenges remain ahead","volume":"526","author":"Bernabeu","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0425","doi-asserted-by":"crossref","first-page":"525684","DOI":"10.1155\/2014\/525684","article-title":"Synthesis and characterization of folate-targeted dextran\/retinoic acid micelles for doxorubicin delivery in acute leukemia","volume":"2014","author":"Varshosaz","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.drudis.2018.05.040_bib0430","first-page":"1","article-title":"General overview of lipid-polymer hybrid nanoparticles, dendrimers, micelles, liposomes, spongosomes and cubosomes","volume":"4","author":"Wakaskar","year":"2017","journal-title":"J. Drug Target"},{"key":"10.1016\/j.drudis.2018.05.040_bib0435","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1556-276X-9-247","article-title":"Dendrimers: synthesis, applications, and properties","volume":"9","author":"Abbasi","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.drudis.2018.05.040_bib0440","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.ijpharm.2016.09.063","article-title":"Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance","volume":"513","author":"Szulc","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0445","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.ijpharm.2015.09.065","article-title":"Maltose modified poly(propylene imine) dendrimers as potential carriers of nucleoside analog 5\u2032-triphosphates","volume":"495","author":"Szulc","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0450","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejps.2013.06.013","article-title":"Development and in vitro evaluation of a novel lipid nanocapsule formulation of etoposide","volume":"50","author":"Saliou","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2018.05.040_bib0455","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1023\/A:1016121319668","article-title":"A novel phase inversion-based process for the preparation of lipid nanocarriers","volume":"19","author":"Heurtault","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2018.05.040_bib0460","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/17425247.2012.673278","article-title":"Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery","volume":"9","author":"Battaglia","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.drudis.2018.05.040_bib0465","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijpharm.2009.04.026","article-title":"Lipid nanocapsules: a new platform for nanomedicine","volume":"379","author":"Huynh","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0470","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1039\/c3sm52781f","article-title":"An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: when the drug is a key player of the nanomedicine structure","volume":"10","author":"Moysan","year":"2014","journal-title":"Soft Matter"},{"key":"10.1016\/j.drudis.2018.05.040_bib0475","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejpb.2011.01.021","article-title":"Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration","volume":"79","author":"Roger","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0480","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.msec.2017.03.099","article-title":"Liquid formulation containing doxorubicin-loaded lipid-core nanocapsules: Cytotoxicity in human breast cancer cell line and in vitro uptake mechanism","volume":"76","author":"Antonow","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.drudis.2018.05.040_bib0485","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.20048","article-title":"Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles","volume":"109","author":"Steiniger","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.drudis.2018.05.040_bib0490","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/10428190109064591","article-title":"Cytosine arabinoside, idarubicin and divided dose etoposide for the treatment of acute myeloid leukemia in elderly patients","volume":"42","author":"Hartmann","year":"2001","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.drudis.2018.05.040_bib0495","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12185-007-0019-6","article-title":"The value of oral cytarabine ocfosfate and etoposide in the treatment of refractory and elderly AML patients","volume":"87","author":"Horikoshi","year":"2008","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0500","doi-asserted-by":"crossref","first-page":"405101","DOI":"10.1088\/0957-4484\/23\/40\/405101","article-title":"Targeting etoposide to acute myelogenous leukaemia cells using nanostructured lipid carriers coated with transferrin","volume":"23","author":"Khajavinia","year":"2012","journal-title":"Nanotechnology"},{"key":"10.1016\/j.drudis.2018.05.040_bib0505","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1166\/jnn.2016.11677","article-title":"Improved in vitro antileukemic activity of all-trans retinoic acid loaded in cholesteryl butyrate solid lipid nanoparticles","volume":"16","author":"Silva","year":"2016","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0510","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijpharm.2009.07.025","article-title":"Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles","volume":"381","author":"Castro","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0515","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.colsurfb.2017.08.030","article-title":"Fabrication of all-trans-retinoic acid-loaded biocompatible precirol: a strategy for escaping dose-dependent side effects of doxorubicin","volume":"159","author":"Sabzichi","year":"2017","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.drudis.2018.05.040_bib0520","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1208\/s12249-011-9733-8","article-title":"Nanostructured lipid carriers (NLC) for parenteral delivery of an anticancer drug","volume":"13","author":"Chinsriwongkul","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.drudis.2018.05.040_bib0525","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1166\/jbn.2010.1120","article-title":"Lipid-core nanocapsules as a nanomedicine for parenteral administration of tretinoin: development and in vitro antitumor activity on human myeloid leukaemia cells","volume":"6","author":"Ourique","year":"2010","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0530","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0535","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1158\/0008-5472.CAN-09-2544","article-title":"Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers","volume":"70","author":"Roberts","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.drudis.2018.05.040_bib0540","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/CAD.0000000000000358","article-title":"A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia","volume":"27","author":"Enjeti","year":"2016","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.drudis.2018.05.040_bib0545","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1166\/jbn.2015.1944","article-title":"Lipid nanosystems enhance the bioavailability and the therapeutic efficacy of FTY720 in acute myeloid leukemia","volume":"11","author":"Estella-Hermoso de Mendoza","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0550","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drudis.2012.08.004","article-title":"Oral delivery of anticancer drugs I: general considerations","volume":"18","author":"Mazzaferro","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2018.05.040_bib0555","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0560","doi-asserted-by":"crossref","first-page":"415102","DOI":"10.1088\/0957-4484\/24\/41\/415102","article-title":"Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine: ex vivo gut permeation studies","volume":"24","author":"Neupane","year":"2013","journal-title":"Nanotechnology"},{"key":"10.1016\/j.drudis.2018.05.040_bib0565","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ijpharm.2014.11.001","article-title":"Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment","volume":"477","author":"Neupane","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.drudis.2018.05.040_bib0570","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.2147\/IJN.S147659","article-title":"Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia","volume":"12","author":"Briot","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.drudis.2018.05.040_bib0575","article-title":"Successful emulation of IV decitabine pharmacokinetics with an oral fixed-dose combination of the oral cytidine deaminase inhibitor (CDAi) E7727 with oral decitabine, in subjects with myelodysplastic syndromes (MDS): final data of phase 1 study","author":"Garcia-Manero","year":"2016","journal-title":"Am. Soc. Hematol."},{"key":"10.1016\/j.drudis.2018.05.040_bib0580","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.drudis.2017.04.008","article-title":"Next-generation superparamagnetic iron oxide nanoparticles for cancer theranostics","volume":"22","author":"Li","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2018.05.040_bib0585","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.drudis.2015.05.009","article-title":"Metal nanoparticles: a theranostic nanotool against cancer","volume":"20","author":"Sharma","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2018.05.040_bib0590","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.colsurfb.2016.01.054","article-title":"Improving antiproliferative effect of the anticancer drug cytarabine on human promyelocytic leukemia cells by coating on Fe3O4@SiO2 nanoparticles","volume":"141","author":"Shahabadi","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.drudis.2018.05.040_bib0595","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.addr.2012.09.038","article-title":"Cancer nanomedicines: so many papers and so few drugs!","volume":"65","author":"Venditto","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.drudis.2018.05.040_bib0600","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1515\/ejnm-2014-0045","article-title":"Is the translational approach becoming a reality in nanomedicine?","volume":"7","author":"Malhaire","year":"2015","journal-title":"Eur J. Nanomed."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618300850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644618300850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:37:26Z","timestamp":1761223046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644618300850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":120,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1359644618300850"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2018.05.040","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in treatment formulations for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2018.05.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}